<DOC>
	<DOCNO>NCT00873236</DOCNO>
	<brief_summary>RATIONALE : Comparing result MRI scan do bevacizumab may help doctor predict patient 's response treatment help plan best treatment . It yet know whether give bevacizumab alone effective give bevacizumab together interferon alpha-2a detect kidney cancer . PURPOSE : This randomized phase II trial study MRI scan blood vessel change cause bevacizumab see well work compare bevacizumab give together interferon alpha-2a treating patient stage III stage IV kidney cancer .</brief_summary>
	<brief_title>MRI Scans Blood Vessel Changes Caused Bevacizumab Alone Given Together With Interferon Alpha-2a Treating Patients With Stage III Stage IV Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish whether bevacizumab-induced change dynamic contrast-enhanced ( DCE ) -MRI vascular parameter significantly enhance recombinant interferon alpha-2a . - To establish whether interferon alpha-2a dose response potentiate bevacizumab-induced change DCE-MRI vascular parameter . Secondary - To correlate change DCE-MRI vascular parameter treatment group progression-free survival . - To correlate change DCE-MRI vascular parameter treatment group tumor response change tumor size . - To correlate change DCE-MRI vascular parameter treatment group surrogate biomarkers . - To assess degree change baseline K^trans within arm treatment . - To investigate change diffusion blood oxygen-level dependent MRI correlation pharmacodynamic endpoint . - To assess efficacy safety profile bevacizumab monotherapy combination low standard dose recombinant interferon alpha-2a . OUTLINE : This multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive bevacizumab IV 30-90 minute every 2 week . - Arm II : Patients receive bevacizumab arm I low-dose recombinant interferon alpha-2a subcutaneously ( SC ) 3 time weekly begin day 0 . - Arm III : Patients receive bevacizumab arm I standard-dose recombinant interferon alpha-2a SC 3 time weekly begin day 0 . After 8 week treatment , recombinant interferon alpha-2a dosage may modify discontinue discretion investigator . Treatment continue absence disease progression unacceptable toxicity . Patients undergo dynamic contrast-enhanced ( gadopentetate dimeglumine ) MRI scan baseline week 2 6 . Peripheral blood serum sample collect baseline week 2 , 6 , 8 analysis surrogate biomarkers flow cytometry mRNA analysis PCR . Archival histopathological specimen analyze IHC , fluorescence resonance-energy transfer , fluorescence lifetime-imaging . Urine sample also collect baseline proteomic profile MALDI-TOF . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced renal cell carcinoma Metastatic ( stage IV ) disease Locally advance ( unresectable stage III ) disease Previously untreated disease Majority component conventional clearcell type mandatory ( tumor mix histology categorize predominant cell type ) Good intermediateprognosis disease define Motzer score Lesions measurable RECIST criterion amenable dynamic contrastenhanced MRI scan No brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL ( may transfuse maintain exceed level ) Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN ( &lt; 5 time ULN patient liver metastasis ) Serum creatinine ≤ 1.5 time ULN Urine dipstick proteinuria &lt; 2+ OR &lt; 1 g protein 24hour urine collection INR ≤ 1.5 Not pregnant nursing Negative pregnancy test Fertile woman must use effective contraception 9 month completion study treatment No significant cardiovascular disease , define follow , within past 6 month : NYHA class IIIV congestive heart failure Unstable angina pectoris Myocardial infarction No significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) symptomatic peripheral vacular disease No evidence history recurrent thromboembolism ( &gt; 1 episode deep venous thrombosis/pulmonary embolism ) within past 6 month , bleed diathesis , coagulopathy No inadequately control hypertension ( define BP &gt; 150 mm Hg systolic and/or &gt; 100 mm Hg diastolic medication ) No history hypertensive crisis hypertensive encephalopathy No stroke transient ischemic attack within past 6 month No abdominal tracheoesophageal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No HIV hepatitis B C infection No active clinically serious bacterial fungal infection ( &gt; CTCAE grade 2 ) No infection &gt; CTCAE grade 2 No concurrent active second malignancy within past 3 year nonmelanoma skin cancer posttreatment localized prostate cancer No gross ascites No seizure disorder require medication No serious nonhealing wound , ulcer , bone fracture No contraindication MRI scanning ( e.g. , history claustrophobia metal fragment implantation ) No history allergic reaction contrast agent No significant medical illness medically significant abnormal laboratory find would , investigator 's opinion , make patient inappropriate study , would increase risk associate patient 's participation study PRIOR CONCURRENT THERAPY : More 28 day since prior major surgery ( include open biopsy ) radiotherapy recover More 14 day since prior palliative radiotherapy painful bone lesion recover Concurrent palliative radiotherapy local pain control allow More 7 day since prior core biopsy minor surgical procedure , exclude placement vascular access device More 30 day since prior concurrent investigational agent No concurrent chronic daily intake aspirin ≥ 325 mg/day clopidogrel &gt; 75 mg/day , steroid ( prednisone &gt; 12.5 mg/day dexamethasone &gt; 2 mg/day ) , exclude inhaled steroid No concurrent bone marrow transplantation stem cell rescue Concurrent anticoagulation allow provide INR &lt; 3 INR therapeutic stable dose coumarintype anticoagulation patient stable dose low molecular weight heparin &gt; 2 week time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>